The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAdvanced Oncotherapy Regulatory News (AVO)

  • This share is currently suspended. It was suspended at a price of 1.925

Share Price Information for Advanced Oncotherapy (AVO)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.925
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.00 (0.00%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1.925
AVO Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Manufacturing Agreement for CCL

25 Nov 2014 07:00

RNS Number : 8653X
Advanced Oncotherapy PLC
25 November 2014
 



25 November 2014

 

ADVANCED ONCOTHERAPY PLC

("Advanced Oncotherapy" or the "Company")

 

Manufacturing agreement for CCL "higher speed accelerators"

 

Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that it has signed a manufacturing agreement with VDL ETG Projects to manufacture the CCL (Coupled Cavity Linac) Accelerating Structures, a key milestone in the development of the LIGHT proton therapy system.

 

At the recent investor day held at the Royal Society of Medicine, Advanced Oncotherapy laid out its development plan and supplier partnering strategy. Today's announcement is a key step on the road to completing the Company's Supplier Partnering Strategy: VDL ETG Projects has an in-depth experience and a track-record in building accelerating modules. The CCL structures or "higher speed accelerators" are an essential part of the LIGHT Accelerator. They consist of a series of cells which accelerate the protons from energies of 37.5 Mega-electron Volts (MeV) to energies that can be applied usefully to a clinical setting (70MeV to 230MeV): 70MeV is the minimum energy suited for superficial tumours such as ocular tumours; the maximum energy of 230MeV has been selected to allow treatment of a central tumour that would be located at the maximum distance from the ideal entry point even in an obese patient.

 

Sanjeev Pandya CEO of Advanced Oncotherapy commented: "Thanks to our existing agreements with Toshiba, ScandiNova and the ENEA institution and with this new agreement, our LIGHT Accelerator System has now all the building blocks in place such that protons can reach their full final energy of 230MeV, an energy that will enable to treat all radiosensitive tumours found in a typical clinical setting. VDL ETG Projects is extremely well regarded in the industry and have successfully worked on building accelerating cavities. I am confident that by working together with their highly experienced team and set up, we will be on track to deliver our first CCL unit at the beginning of next year."

 

Bob Rose, Global Manufacturing & Supply Chain Director of Advanced Oncotherapy said: "VDL ETG Projects' experience and capabilities in manufacturing high-precision parts will serve to rapidly accelerate the development of our CCL modules. The relationship affirms our focus in creating innovative products and commitment to delivering this revolutionary piece of technology into the market - we are delighted to have VDL on board."

 

Guustaaf Savenije CTO of VDL ETG commented: "I am very pleased to be working with Advanced Oncotherapy, and that the Company has chosen VDL ETG Projects as their partner to build the CCL Accelerating Structures. AVO's LIGHT System technology is highly innovative and really represents one of the most exciting developments in the industry."

 

Advanced Oncotherapy Plc

www.avoplc.com

Sanjeev Pandya, CEO

Tel: +44 20 3617 8728

Nicolas Serandour, CFO

Westhouse Securities (Nomad & Joint Broker)

Tel: +44 20 7601 6100

Antonio Bossi / David Coaten

Beaufort Securities (Joint Broker)

Tel: +44 20 7382 8300

Saif Janjua / Jon Levinson

Walbrook PR (Financial PR & IR)

Tel: +44 20 7933 8780 or avo@walbrookpr.com

Paul McManus / Anna Dunphy

Mob: +44 7980 541 893 / Mob: +44 7876 741 001

 

About Advanced Oncotherapy Plc www.avoplc.com

 

Advanced Oncotherapy's team based at CERN in Geneva focuses on the development of a proprietary proton accelerator called Linac Image Guided Hadron Technology (LIGHT). LIGHT accelerates protons to the energy levels achieved in legacy machines but in a unit that is a quarter of the size and between a quarter and a fifth of the cost. This compact configuration delivers proton beams in a way that facilitates a greater precision and electronic control which is not achievable with older technologies.

 

Advanced Oncotherapy is a provider of particle therapy with protons that harnesses the best in modern technology. As a result, Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with an innovative technology as well as better health outcomes and lower treatment related side effects.

 

Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of an innovative and cost-effective system for particle therapy with protons.

 

 

About VDL ETG Projects

 

With head offices and manufacturing facilities in Eindhoven, VDL ETG Projects specialises in the (co)development of high precision parts, prototypes, sub-assemblies, modules and complete mass manufacturing equipment. VDL ETG has capabilities in high precision manufacturing in interlocking domains of Medical, Science & Technology, Semiconductors to Solar & Energy.

VDL ETG & VDL ETG Projects are part of VDL Groep. VDL Groep, with its head office in Eindhoven (The Netherlands), is an international industrial company focused on the development, production and sales of semi-finished products, buses and coaches and other finished products and the assembly of cars. Since the founding in 1953 this family-owned company has grown to include 85 operating companies, spread over 19 countries with approximately 10,000 employees. The strength of VDL Groep lies in the mutual cooperation between the companies.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCUSABRSOAAUAA
Date   Source Headline
3rd May 20248:54 amRNSFurther update on financing discussions
2nd Apr 20243:50 pmRNSFurther update on financing discussions
29th Feb 20245:19 pmRNSFurther update on financing discussions
1st Feb 20247:00 amRNSFurther update on financing discussions
9th Jan 20249:00 amRNSUpdate on Financing Discussions
23rd Oct 20237:00 amRNSUpdate on Financing and Current Financial Position
17th Jul 20237:00 amRNSRecapitalisation and funding plan, update on FSP
30th Jun 20235:00 pmRNSTotal Voting Rights
30th Jun 20237:30 amRNSSuspension - Advanced Oncotherapy PLC
30th Jun 20237:15 amRNSUpdate on financing, suspension of trading on AIM
29th Jun 20231:35 pmRNSHolding(s) in Company
29th Jun 20239:59 amRNSForm 8.3 - Advanced Oncotherapy PLC
28th Jun 202310:25 amRNSForm 8.3 - Advanced Oncotherapy PLC
27th Jun 202310:29 amRNSForm 8.3 - Advanced Oncotherapy
27th Jun 202310:25 amRNSForm 8.3 - Advanced Oncotherapy
26th Jun 20234:26 pmRNSForm 8.3 - Advanced Oncotherapy
26th Jun 202310:57 amRNSPartial conversion of Convertible Notes
23rd Jun 202311:05 amRNSHolding(s) in Company
23rd Jun 20239:30 amRNSForm 8.3 - Advanced Oncotherapy PLC
20th Jun 20235:28 pmRNSHolding(s) in Company
19th Jun 20235:56 pmRNSPartial conversion of Convertible Notes
19th Jun 20231:48 pmRNSForm 8.3 - Advanced Oncotherapy PLC
16th Jun 20236:23 pmRNSIssue of warrants
13th Jun 202311:46 amRNSForm 8.3 - Advanced Oncotherapy PLC
31st May 20235:57 pmRNSUpdate on financing and convertible notes
30th May 202310:42 amRNSForm 8.3 - Advanced Oncotherapy Plc
24th May 20235:54 pmRNSForm 8 (OPD) Advanced Oncotherapy plc
24th May 20235:29 pmRNSForm 8.3 - Advanced Oncotherapy - Cosylab d.d.
22nd May 20232:59 pmRNSForm 8.3 - Advanced Oncotherapy plc
19th May 202312:09 pmRNSForm 8.3 - Advanced Oncotherapy PLC
17th May 20232:58 pmRNSForm 8.3 - Advanced Oncotherapy plc
15th May 202311:36 amRNSUpdate on Convertible Note & Loan Extension
15th May 20239:19 amRNSForm 8.3 - Advanced Oncotherapy Plc
12th May 202312:53 pmRNSForm 8.3 - Advanced Oncotherapy - Minmetco Limited
11th May 20235:14 pmRNSForm 8.3 - Advanced Oncotherapy - eQ Blue Planet
11th May 202311:17 amRNSForm 8.3 - Advanced Oncotherapy - Atlantic Cedar
10th May 202311:34 amRNSForm 8.3 - Advanced Oncotherapy plc
9th May 20234:40 pmRNSForm 8.3 - Advanced Oncotherapy - Baltisches Haus
9th May 20234:37 pmRNSForm 8.3 - Advanced Oncotherapy plc
9th May 20234:36 pmRNSForm 8.3 - Advanced Oncotherapy plc
5th May 20238:56 amRNSFORM 8.3 - Advanced Oncotherapy
5th May 20237:00 amRNSAdditional funding from Secured Convertible Note
4th May 20235:01 pmRNSForm 8.3 - Advanced Oncotherapy Plc
4th May 20233:55 pmRNSChange of Registered Office
3rd May 20236:19 pmRNSRule 2.9 Announcement
3rd May 20234:28 pmRNSForm 8.3 - Advanced Oncotherapy PLC
2nd May 20236:19 pmRNSForm 8 (OPD) Advanced Oncotherapy plc
18th Apr 20237:00 amRNSStrategic review and formal sale process
31st Mar 20236:05 pmRNSHolding(s) in Company
20th Mar 202312:36 pmRNSUpdate on Secured Convertible Note Facility

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.